Core Insights - Perspective Therapeutics, Inc. is focused on advancing its proprietary radiopharmaceutical technology to redefine cancer treatment and aims to share maturing clinical data across all programs in 2026 [2][18] Clinical Pipeline Updates - The company is conducting a multi-center open-label dose-finding study of [Pb]VMT-α-NET for patients with unresectable or metastatic somatostatin receptor type 2-positive neuroendocrine tumors [3] - Updated interim data from the study presented at ASCO-GI 2026 showed that 76% of patients in a specific cohort were without progression and remained alive [7][8] - VMT-α-NET continues to demonstrate strong patient recruitment and is well-tolerated, with no reports of dose-limiting toxicities [6][7] - Clinical updates for VMT01 targeting melanoma and PSV359 targeting FAP across multiple solid tumors are expected in mid to late 2026 [6] Manufacturing Infrastructure - The company is expanding its manufacturing capabilities by enhancing capacity at existing facilities and building out recently acquired sites [15] Upcoming Events - The CEO will present updates at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [17]

Clinical Trial Updates - Perspective Therapeutics, Inc. announced updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for treating unresectable or metastatic neuroendocrine tumors[8] - The data presentation occurred at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium held from January 8-10, 2026[8]

Core Viewpoint - Perspective Therapeutics, Inc. announced updated interim results from its Phase 1/2a clinical trial of [Pb]VMT-α-NET for treating unresectable or metastatic neuroendocrine tumors, presented at the 2026 ASCO Gastrointestinal Cancers Symposium [1] Clinical Trial Results - The interim results are based on a data cut-off date of December 10, 2025, including safety data from 56 patients across three dose cohorts and efficacy analysis from two patients in Cohort 1 and 23 patients in Cohort 2 [2] - Updated interim results show that [Pb]VMT-α-NET continues to be well-tolerated with no reports of dose limiting toxicities (DLTs) or serious treatment-related complications [6][7] - Objective response rate in Cohort 2 is 39%, with 9 patients showing response according to RECIST v1.1, including 8 previously confirmed responders [6][7] Safety Profile - Among the 56 patients analyzed for safety, 21 patients (37.5%) experienced Grade 3 or higher treatment-emergent adverse events, with one transient Grade 4 event reported [7] - Serious adverse events were reported in five patients, none of which were deemed related to the study medication [7] Efficacy Insights - The updated efficacy analysis suggests durable disease control and deepening of tumor response in the first 23 patients of Cohort 2 and both patients in Cohort 1 [6] - 19 of the 25 patients (76%) from the previous ESMO presentation were without progression and remained alive, including both patients in Cohort 1 [7] Future Plans - The company plans to submit additional efficacy data for the remaining patients in Cohort 2 and eight patients in Cohort 3 to more medical conferences in 2026, along with regulatory engagement [6][9] - The Chief Medical Officer emphasized the compelling clinical profile of VMT-α-NET and the completion of DLT assessment for the higher dose cohort, allowing for the enrollment of more patients [8]

Core Viewpoint - Perspective Therapeutics, Inc. is advancing its radiopharmaceutical development for cancer treatments and will present at the upcoming J.P. Morgan Healthcare Conference [1][2]. Company Overview - Perspective Therapeutics, Inc. specializes in radiopharmaceuticals, focusing on innovative cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [2]. - The company is developing complementary imaging diagnostics that utilize the same targeting moieties, enhancing personalized treatment and patient outcomes through a "theranostic" approach [2]. Clinical Programs - The company's clinical programs include neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359), which are currently in Phase 1/2a imaging and therapy trials in the U.S. [3]. - Perspective is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3].

Core Insights - Perspective Therapeutics, Inc. announced that updated data on its [Pb]VMT-α-NET program will be presented at the ASCO-GI Congress 2026, scheduled for January 8 to 10, 2026 [1][2] Group 1: Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for various cancers, utilizing proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [4][5] - The company is conducting a multi-center, open-label, dose-escalation study of [Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors [3][4] Group 2: Clinical Data and Efficacy - As of the data cut-off date of September 12, 2025, safety findings from 55 patients indicated a favorable safety profile for [²¹²Pb]VMT-α-NET, with no dose-limiting toxicities or Grade 4 or 5 treatment-emergent adverse events reported [4][6] - Among 25 patients evaluated, 20 (80%) remained progression-free, and 8 patients achieved confirmed responses, all from Cohort 2, with a median follow-up of 41 weeks [6]

Summary of Perspective Therapeutics FY Conference Call Company Overview - **Company**: Perspective Therapeutics (NYSEAM:CATX) - **Focus**: Radiopharmaceuticals, specifically targeting various isotopes and chelator technologies for cancer treatment Key Industry Insights - **Radiopharmaceutical Market**: The field has evolved significantly over the past 30 years, moving from Iodine-131 to more advanced isotopes like Lutetium-177 and Actinium-225, which offer better targeting and efficacy [3][4] - **Emerging Isotopes**: Lead-212 is highlighted as a potent alpha emitter with significant potential for tumor destruction, alongside other isotopes like astatine and terbium [5][6] Core Product Development - **VMT-NET Program**: Targets SSTR2 positive tumors, showing a promising overall response rate (ORR) of 44% compared to Lutathera's 13% [12][15] - **Safety Profile**: VMT-NET has demonstrated a clean safety profile with no significant adverse events reported, which is crucial for patients with chronic conditions [19][14] - **Clinical Data**: Recent data presented at ESMO indicates strong therapeutic and clinical profiles, with a surge in physician interest for patient enrollment [13][22] Competitive Landscape - **Comparison with Competitors**: The VMT-NET program shows superior efficacy and safety compared to competitor programs from Sanofi and others, which reported lower ORR and safety concerns [20][21] - **Market Positioning**: The company aims to establish itself as a leader in the radiopharmaceutical space by addressing unmet medical needs and providing safer, more effective treatment options [11][12] Future Development and Regulatory Strategy - **FDA Engagement**: The company is actively preparing for discussions with the FDA regarding registrational trials, focusing on safety and efficacy data [24][41] - **Ongoing Trials**: The company is currently enrolling patients in multiple programs, with plans to present data at medical conferences next year [37][38] Financial Health - **Cash Runway**: The company has a cash runway extending until the end of 2026, with $172 million on the balance sheet and a historical burn rate of $20 million per quarter [41][42] - **Manufacturing Capacity**: Perspective Therapeutics has operational sites in Iowa and New Jersey, with additional facilities in development across major cities, enhancing its production capabilities [43] Additional Programs - **MC1R and FAP Programs**: The company is exploring innovative approaches to target melanoma and solid tumors, respectively, with promising preclinical data [30][32][35] Conclusion - **Strategic Vision**: Perspective Therapeutics is positioned to leverage its innovative radiopharmaceuticals to transform cancer treatment, focusing on safety, efficacy, and addressing significant unmet medical needs in oncology [29][31]

Core Insights - Perspective Therapeutics, Inc. is focused on developing advanced radiopharmaceutical treatments for various cancers using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells specifically [2][3] Group 1: Company Overview - Perspective Therapeutics is pioneering advanced treatments for cancers throughout the body with a focus on radiopharmaceuticals [2] - The company utilizes a "theranostic" approach, combining treatment and imaging diagnostics to personalize cancer therapy and optimize patient outcomes [2] - The company is currently conducting Phase 1/2a imaging and therapy trials for its neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs in the U.S. [3] Group 2: Upcoming Events - Members of the senior leadership team will participate in the Piper Sandler & Co. 37th Annual Healthcare Conference on December 2, 2025, from 1:00 to 1:25 p.m. ET in New York, NY [1] - The company will also be present at the Evercore 8th Annual Healthcare Conference on December 3, 2025, from 3:00 to 3:20 p.m. ET in Miami, FL [1] Group 3: Operational Developments - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3]

Group 1 - The management team of Perspective Therapeutics is open to questions from the audience, utilizing a QR code for submissions [1] - The focus of Perspective Therapeutics includes key clinical programs that are currently in development [2]

Financial Performance - Grant revenue for Q3 2025 was $209,000, a decrease of 43% compared to $369,000 in Q3 2024[15] - Total operating expenses for Q3 2025 were $28,070,000, up 48% from $19,003,000 in Q3 2024[15] - Net loss from continuing operations for Q3 2025 was $25,969,000, compared to a loss of $15,122,000 in Q3 2024, representing a 72% increase in losses[15] - The company reported a net loss of $65,631,000 for the nine months ended September 30, 2025, compared to a loss of $39,110,000 for the same period in 2024, reflecting a 68% increase in losses[17] - The company experienced a net loss of $25.969 million for the quarter ended September 30, 2025, compared to a net loss of $21.485 million for the previous quarter[30] - Total operating expenses for the nine months ended September 30, 2025, were $74.573 million, up from $47.122 million in 2024[15] Cash and Liquidity - Cash, cash equivalents, and restricted cash at the end of Q3 2025 were $26,762,000, down from $226,443,000 at the end of Q3 2024[17] - As of September 30, 2025, the company reported cash, cash equivalents, and short-term investments of $174.1 million, with a total accumulated deficit of $297.4 million[30] - The company plans to fund its operations into late 2026 with its current cash reserves, but may seek additional capital through various means[31] - The Company has $24.4 million in cash equivalents as of September 30, 2025, down from $59.7 million at the end of 2024[77] - The total cash equivalents and available-for-sale securities as of September 30, 2025, were $171.800 million, compared to $225.056 million as of December 31, 2024[80] Shareholder Activities - The total number of shares outstanding increased from 70,671,464 at December 31, 2024, to 74,337,990 at September 30, 2025, reflecting the issuance of common stock[19] - A 1-for-10 reverse stock split was executed on June 14, 2024, affecting all stockholders uniformly[28] - Share-based compensation expenses were $2.156 million for the quarter ended September 30, 2025[19] - The Company reported a basic and diluted loss per share, calculated by dividing net loss by the weighted average number of shares outstanding, which did not include potentially dilutive common stock equivalents[35] - As of September 30, 2025, there were 10,902,610 total potentially dilutive securities, compared to 7,667,413 as of September 30, 2024, indicating an increase of approximately 42.5%[36] Business Operations - The company has not generated revenue from commercial products and incurs the majority of its operating expenses in the United States[29] - The company has a single operating segment focused on radiopharmaceutical development, with no significant changes in accounting policies reported[29] - The company is focused on obtaining regulatory approvals for its future program candidates, including Fast Track designation for PSV359 from the FDA[8] - The company is leveraging technology to identify and develop future program candidates, aiming to enhance its competitive position in the market[8] Asset Management - As of September 30, 2025, the Company's property and equipment, net, was valued at $64.4 million, an increase from $57.3 million as of December 31, 2024[74] - The Company holds indefinite-lived intangible assets valued at $50.0 million, representing the estimated fair value of its pipeline of acquired radiotherapy program candidates[75] - The Company recognized a total gain from discontinued operations of $514,000 for the nine months ended September 30, 2025, while incurring a loss of $949,000 for the same period in 2024[69] Financing Activities - The Company entered into a 2024 ATM Agreement allowing for the sale of up to $250.0 million of Common Stock, with a commission of up to 3.0% on gross proceeds from each sale[39][40] - The Company raised approximately $10.2 million from the sale of 3,379,377 shares at an average price of $3.02 per share under the 2024 ATM Agreement on February 18, 2025[43] - The gross proceeds from the May 2024 Registered Offering were approximately $80.0 million, before underwriting discounts and commissions[45] - The Company completed a private placement on March 6, 2024, raising approximately $87.4 million from the sale of 9,200,998 shares at $9.50 per share[48] - The Company sold 5,634,235 shares to Lantheus for a total of $50.0 million, representing 19.99% of the outstanding shares as of January 8, 2024[51] Lease and Liability Management - The Company recognized a right-of-use asset and lease liability of approximately $1.1 million upon entering into a lease for lab and office space effective April 1, 2024[91] - The Company recognized a right-of-use asset and lease liability of approximately $0.6 million upon entering a lease for office space in Somerset, NJ, which terminates on November 30, 2028[93] - The Company entered into a lease with Unico Properties LLC for office space in Seattle, WA, recognizing a right-of-use asset and lease liability of approximately $0.8 million, terminating in October 2028[95] - The Company's operating lease expense was $0.3 million for the three months ended September 30, 2024, and $0.8 million for the nine months ended September 30, 2025[96] - The total future operating lease payments as of September 30, 2025, amount to $1.863 million, with a total lease liability of $1.675 million after accounting for imputed interest[97] Regulatory and Compliance - The company anticipates potential impacts from U.S. and international trade policies on costs for supplies and materials used in drug development[8] - The Company has accrued an estimated liability of $0.2 million related to settlement negotiations with stockholder plaintiff firms as of September 30, 2025[84] - The Company reduced its estimated liability for hazardous waste removal by $0.3 million, resulting in an estimated liability of $0.2 million as of September 30, 2025[98]

Core Insights - Perspective Therapeutics, Inc. is advancing its clinical programs in radiopharmaceuticals aimed at cancer treatment, with a focus on neuroendocrine tumors, melanoma, and solid tumors [2][24][25] Clinical Highlights - The company is conducting a multi-center, open-label study of [Pb]VMT-α-NET targeting SSTR2-positive neuroendocrine tumors, with interim data presented at major medical conferences [3][4][7] - Updated interim results show a favorable safety profile for [Pb]VMT-α-NET, with no dose-limiting toxicities reported and 80% of patients remaining progression-free [8][9] - Cohort 3 of the [Pb]VMT-α-NET study opened in June 2025, with patients receiving up to four doses every eight weeks [9][10] Financial Summary - As of September 30, 2025, the company had approximately $174 million in cash and short-term investments, down from $227 million at the end of 2024, which is expected to fund operations into late 2026 [7][16][17] - Research and development expenses increased by approximately 69% year-over-year for Q3 2025, totaling $20.3 million, primarily due to increased clinical activities and personnel costs [20] - The net loss for Q3 2025 was $26 million, or $0.35 per share, compared to a net loss of $15.1 million, or $0.21 per share, for the same period in 2024 [23][30] Operational Developments - The company has transitioned its operations to focus on continuing operations following the divestiture of its brachytherapy segment in April 2024 [18] - The company is also developing complementary imaging diagnostics to enhance treatment personalization and optimize patient outcomes [24] Future Outlook - The company anticipates sharing updates on its clinical-stage medicines throughout 2026, with strong patient recruitment and clinical site engagement [7][11] - Plans are in place to submit data from ongoing studies to medical conferences in the coming year [11][12]